27 April 2016 - Novartis announced today that the US FDA has granted three breakthrough therapy designations for Ilaris (canakinumab) to treat three rare types of periodic fever syndromes, also known as hereditary periodic fevers.

Periodic fever syndromes are a group of autoinflammatory diseases that cause disabling and recurrent fevers, which may be accompanied by joint pain and swelling, muscle pain and skin rashes, with complications that can be life-threatening. Most patients present with symptoms in infancy or childhood. The three conditions for which Ilaris is being reviewed are tumour necrosis factor-receptor associated periodic syndrome and hyperimmunoglobulin D syndrome/mevalonate kinase deficiency, as well as familial Mediterranean fever not adequately controlled with colchicine.

For more details, go to: https://www.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare